Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | CTSD | P07339 | 1/20 | 0.39 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.39 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6177152 | 0.86 | TSHR (0.44) | ALDH1A1L3MBTL1POLBMEN1KMT2A | |
| SCHEMBL28569136 | 0.82 | L3MBTL1 (0.50) | ALDH1A1L3MBTL1NPSR1MEN1KMT2A | |
| SCHEMBL7979095 | 0.80 | POLB (0.48) | ALDH1A1L3MBTL1POLBNPSR1HTT | |
| SCHEMBL30669705 | 0.80 | POLB (0.48) | ALDH1A1L3MBTL1POLBNPSR1HTT | |
| SCHEMBL28140055 | 0.79 | POLB (0.45) | ALDH1A1L3MBTL1POLBNPSR1HTT | |
| SCHEMBL28588425 | 0.78 | ALDH1A1 (0.45) | ALDH1A1L3MBTL1POLBNPSR1HTT | |
| SCHEMBL23880085 | 0.77 | CTSD (0.47) | L3MBTL1POLBNPSR1HTTLMNA | |
| SCHEMBL2830617 | 0.77 | L3MBTL1 (0.38) | ALDH1A1L3MBTL1POLBNPSR1HTT | |
| SCHEMBL9430235 | 0.77 | KDM4E (0.43) | ALDH1A1L3MBTL1MEN1KMT2ALMNA | |
| SCHEMBL28915627 | 0.77 | PPARG (0.52) | ALDH1A1L3MBTL1POLBNPSR1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1061921-A4 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2005-03-30 | — | — | EP | disclosed |
| US-20020147334-A1 | Vitronectin Receptor Antagonists | SMITHKLINE BEECHAM CORPORATION | 2002-10-10 | — | — | US | disclosed |
| EP-1061921-A1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-12-27 | — | — | EP | disclosed |
| WO-1999045927-A1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020147334-A1 | Vitronectin Receptor Antagonists | ADGRF1, FN1, CALCR | ALDH1A1 2759/4885L3MBTL1 4658/4885POLB 4120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.